Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Losartan
Drug ID BADD_D01322
Description Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status Prescription; Discontinued
ATC Code C09CA01
DrugBank ID DB00678
KEGG ID D08146
MeSH ID D019808
PubChem ID 3961
TTD Drug ID D0DD0K
NDC Product Code Not Available
Synonyms Losartan | 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol | DuP-753 | DuP 753 | DuP753 | MK-954 | MK 954 | MK954 | Cozaar | Losartan Potassium | Potassium, Losartan | Losartan Monopotassium Salt | Monopotassium Salt, Losartan | Salt, Losartan Monopotassium
Chemical Information
Molecular Formula C22H23ClN6O
CAS Registry Number 114798-26-4
SMILES CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Capillary fragility increasedInterleukin-1 alphaP01583T1634026156105
Capillary fragility increasedInterleukin-10P29456Not Available26156105
Capillary fragility increasedC-C motif chemokine 2P14844Not Available26156105
Metabolic disorderCytochrome P450 2C9P11712T192449663807; 11434505; 9825828
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pyelonephritis20.01.09.001; 11.01.14.0020.000049%Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.06.003--Not Available
Rash generalised23.03.13.0020.000218%Not Available
Rash maculo-papular23.03.13.004--
Rash pruritic23.03.12.0020.000170%Not Available
Rash vesicular23.03.13.0090.000073%Not Available
Rectal cancer16.13.01.003; 07.21.05.0020.000013%Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Red blood cell count decreased13.01.05.0070.000315%Not Available
Renal cyst16.27.01.001; 20.01.04.0010.000073%Not Available
Renal disorder20.01.02.0020.000291%Not Available
Renal failure20.01.03.0050.000165%Not Available
Renal tubular disorder20.05.03.0040.000049%Not Available
Respiratory disorder22.02.07.0020.000097%Not Available
Respiratory distress22.02.01.012--Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
Restlessness19.11.02.002; 17.02.05.021--
Retinal detachment12.01.04.004; 06.09.03.0030.000049%
Rhabdomyolysis15.05.05.002--
Rhinitis22.07.03.006; 11.01.13.0040.000049%
Seizure17.12.03.001--
Sepsis11.01.11.0030.000114%
Septic shock24.06.02.011; 11.01.11.004--Not Available
Serum ferritin decreased13.11.01.0310.000049%Not Available
Serum ferritin increased13.11.01.0260.000073%Not Available
Shock24.06.02.002--Not Available
Sialoadenitis11.01.04.002; 07.06.04.002--
Sinus bradycardia02.03.03.009--
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 19 Pages